2 completed, 1 approved for marketing, 1 withdrawn. 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Cangene Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B IB1001 - Hemophilia B | Phase 3 | Withdrawn | Cangene Corporation | 2014-03-01 | 2016-08-23 | |
| Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG)) - Hepatitis B | Phase 4 | Completed | Georgetown University | 5 | 2009-10-01 | 2015-09-28 |
| Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients HepaGam B - Hepatitis B, Liver Transplantation | Phase 4 | Completed | Cangene Corporation | 9 | 2008-02-01 | 2013-11-01 |
| Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection VariZIG™ - Varicella | Approved for marketing | Cangene Corporation | 2006-02-01 | 2013-04-04 |
Hepatitis B (2) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Chickenpox (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Hemophilia A (1) · Hemophilia B (1) · Hemorrhagic Disorders (1) · Infections (1)
hepatitis B hyperimmune globulin (2) · IB1001 (1) · varicella-zoster immune globulin (1)
United States (3) · Canada (1) · United Kingdom (1)
Kirti Shetty, MD (1) · Robert Gale, MD (1)